Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

clarivate
OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
9 "Blood glucose"
Filter
Filter
Article type
Keywords
Publication year
Authors
Funded articles
Original Article
Effects of an Electronic Medical Records-Linked Diabetes Self-Management System on Treatment Targets in Real Clinical Practice: Retrospective, Observational Cohort Study
So Jung Yang, Sun-Young Lim, Yoon Hee Choi, Jin Hee Lee, Kun-Ho Yoon
Received November 10, 2023  Accepted January 22, 2024  Published online March 21, 2024  
DOI: https://doi.org/10.3803/EnM.2023.1878    [Epub ahead of print]
  • 168 View
  • 3 Download
AbstractAbstract PDF
Background
This study evaluated the effects of a mobile diabetes management program called “iCareD” (College of Medicine, The Catholic University of Korea) which was integrated into the hospital’s electronic medical records system to minimize the workload of the healthcare team in the real clinical practice setting.
Methods
In this retrospective observational study, we recruited 308 patients. We categorized these patients based on their compliance regarding their use of the iCareD program at home; compliance was determined through self-monitored blood glucose inputs and message subscription rates. We analyzed changes in the ABC (hemoglobin A1c, blood pressure, and low-density lipoprotein cholesterol) levels from the baseline to 12 months thereafter, based on the patients’ iCareD usage patterns.
Results
The patients comprised 92 (30%) non-users, 170 (55%) poor-compliance users, and 46 (15%) good-compliance users; the ABC target achievement rate showed prominent changes in good-compliance groups from baseline to 12 months (10.9% vs. 23.9%, P<0.05), whereas no significant changes were observed for poor-compliance users and non-users (13.5% vs. 18.8%, P=0.106; 20.7% vs. 14.1%, P=0.201; respectively).
Conclusion
Implementing the iCareD can improve the ABC levels of patients with diabetes with minimal efforts of the healthcare team in real clinical settings. However, the improvement of patients’ compliance concerning the use of the system without the vigorous intervention of the healthcare team needs to be solved in the future.
Close layer
Review Articles
Diabetes, obesity and metabolism
The Benefits Of Continuous Glucose Monitoring In Pregnancy
Jee Hee Yoo, Jae Hyeon Kim
Endocrinol Metab. 2023;38(5):472-481.   Published online October 11, 2023
DOI: https://doi.org/10.3803/EnM.2023.1805
  • 2,130 View
  • 187 Download
  • 1 Web of Science
  • 1 Crossref
AbstractAbstract PDFPubReader   ePub   
Previous studies have consistently demonstrated the positive effects of continuous glucose monitoring (CGM) on glycemic outcomes and complications of diabetes in people with type 1 diabetes. Guidelines now consider CGM to be an essential and cost-effective device for managing type 1 diabetes. As a result, insurance coverage for it is available. Evidence supporting CGM continues to grow and expand to broader populations, such as pregnant people with type 1 diabetes, people with type 2 diabetes treated only with basal insulin therapy, and even type 2 diabetes that does not require insulin treatment. However, despite the significant risk of hyperglycemia in pregnancy, which leads to complications in more than half of affected newborns, CGM indications and insurance coverage for those patients are unresolved. In this review article, we discuss the latest evidence for using CGM to offer glycemic control and reduce perinatal complications, along with its cost-effectiveness in pregestational type 1 and type 2 diabetes and gestational diabetes mellitus. In addition, we discuss future prospects for CGM coverage and indications based on this evidence.

Citations

Citations to this article as recorded by  
  • Wearable devices for glucose monitoring: A review of state-of-the-art technologies and emerging trends
    Mohammad Mansour, M. Saeed Darweesh, Ahmed Soltan
    Alexandria Engineering Journal.2024; 89: 224.     CrossRef
Close layer
Diabetes, Obesity and Metabolism
Recent Updates to Clinical Practice Guidelines for Diabetes Mellitus
Jin Yu, Seung-Hwan Lee, Mee Kyoung Kim
Endocrinol Metab. 2022;37(1):26-37.   Published online February 28, 2022
DOI: https://doi.org/10.3803/EnM.2022.105
  • 15,579 View
  • 1,110 Download
  • 18 Web of Science
  • 18 Crossref
AbstractAbstract PDFPubReader   ePub   
Guidelines for the management of patients with diabetes have become an important part of clinical practice that improve the quality of care and help establish evidence-based medicine in this field. With rapidly accumulating evidence on various aspects of diabetes care, including landmark clinical trials of treatment agents and newer technologies, timely updates of the guidelines capture the most current state of the field and present a consensus. As a leading academic society, the Korean Diabetes Association publishes practice guidelines biennially and the American Diabetes Association does so annually. In this review, we summarize the key changes suggested in the most recent guidelines. Some of the important updates include treatment algorithms emphasizing comorbid conditions such as atherosclerotic cardiovascular disease, heart failure, and chronic kidney disease in the selection of anti-diabetic agents; wider application of continuous glucose monitoring (CGM), insulin pump technologies and indices derived from CGM such as time in range; more active screening of subjects at high-risk of diabetes; and more detailed individualization in diabetes care. Although there are both similarities and differences among guidelines and some uncertainty remains, these updates provide a good approach for many clinical practitioners who are battling with diabetes.

Citations

Citations to this article as recorded by  
  • Use of Diabetes Medications before and after a Heart Failure–Related Hospitalization among Nursing Home Residents
    Tingting Zhang, Andrew R. Zullo, Kaleen (Kaley) N. Hayes, Dae Hyun Kim, Yoojin Lee, Lori A. Daiello, Douglas P. Kiel, Sarah D. Berry
    Journal of the American Medical Directors Association.2024; 25(3): 454.     CrossRef
  • Accuracy and Safety of the 15-Day CareSens Air Continuous Glucose Monitoring System
    Kyung-Soo Kim, Seung-Hwan Lee, Won Sang Yoo, Cheol-Young Park
    Diabetes Technology & Therapeutics.2024;[Epub]     CrossRef
  • Body composition and metabolic syndrome in patients with type 1 diabetes
    Qiong Zeng, Xiao-Jing Chen, Yi-Ting He, Ze-Ming Ma, Yi-Xi Wu, Kun Lin
    World Journal of Diabetes.2024; 15(1): 81.     CrossRef
  • The best internal structure of the Diabetes Quality of Life Measure (DQOL) in Brazilian patients
    Denilson Menezes Almeida, Aldair Darlan Santos-de-Araújo, José Mário Costa Brito Júnior, Marcela Cacere, André Pontes-Silva, Cyrene Piazera Costa, Maria Cláudia Gonçalves, José Márcio Soares Leite, Almir Vieira Dibai-Filho, Daniela Bassi-Dibai
    BMC Public Health.2024;[Epub]     CrossRef
  • Diabetes Duration, Cholesterol Levels, and Risk of Cardiovascular Diseases in Individuals With Type 2 Diabetes
    Mee Kyoung Kim, Kyu Na Lee, Kyungdo Han, Seung-Hwan Lee
    The Journal of Clinical Endocrinology & Metabolism.2024;[Epub]     CrossRef
  • A nationwide cohort study on diabetes severity and risk of Parkinson disease
    Kyungdo Han, Bongsung Kim, Seung Hwan Lee, Mee Kyoung Kim
    npj Parkinson's Disease.2023;[Epub]     CrossRef
  • Optimal Low-Density Lipoprotein Cholesterol Level for Primary Prevention in Koreans with Type 2 Diabetes Mellitus
    Ji Yoon Kim, Nam Hoon Kim
    Diabetes & Metabolism Journal.2023; 47(1): 42.     CrossRef
  • Efficacy and safety of enavogliflozin versus dapagliflozin added to metformin plus gemigliptin treatment in patients with type 2 diabetes: A double-blind, randomized, comparator-active study: ENHANCE-D study
    Kyung-Soo Kim, Kyung Ah Han, Tae Nyun Kim, Cheol-Young Park, Jung Hwan Park, Sang Yong Kim, Yong Hyun Kim, Kee Ho Song, Eun Seok Kang, Chul Sik Kim, Gwanpyo Koh, Jun Goo Kang, Mi Kyung Kim, Ji Min Han, Nan Hee Kim, Ji Oh Mok, Jae Hyuk Lee, Soo Lim, Sang S
    Diabetes & Metabolism.2023; 49(4): 101440.     CrossRef
  • Finerenone: Efficacy of a New Nonsteroidal Mineralocorticoid Receptor Antagonist in Treatment of Patients With Chronic Kidney Disease and Type 2 Diabetes
    Subo Dey, Jasmine Garg, Andy Wang, Eva Holzner, William H. Frishman, Wilbert S. Aronow
    Cardiology in Review.2023;[Epub]     CrossRef
  • Impact of mental disorders on the risk of heart failure among Korean patients with diabetes: a cohort study
    Tae Kyung Yoo, Kyung-Do Han, Eun-Jung Rhee, Won-Young Lee
    Cardiovascular Diabetology.2023;[Epub]     CrossRef
  • Chronic disease management program applied to type 2 diabetes patients and prevention of diabetic complications: a retrospective cohort study using nationwide data
    Min Kyung Hyun, Jang Won Lee, Seung-Hyun Ko
    BMC Public Health.2023;[Epub]     CrossRef
  • Innovative Therapeutic Approaches in Non-Alcoholic Fatty Liver Disease: When Knowing Your Patient Is Key
    Marta Alonso-Peña, Maria Del Barrio, Ana Peleteiro-Vigil, Carolina Jimenez-Gonzalez, Alvaro Santos-Laso, Maria Teresa Arias-Loste, Paula Iruzubieta, Javier Crespo
    International Journal of Molecular Sciences.2023; 24(13): 10718.     CrossRef
  • Association between type 2 diabetes mellitus and depression among Korean midlife women: a cross-sectional analysis study
    You Lee Yang, Eun-Ok Im, Yunmi Kim
    BMC Nursing.2023;[Epub]     CrossRef
  • Access to novel anti-diabetic agents in resource limited settings: A brief commentary
    Poobalan Naidoo, Kiolan Naidoo, Sumanth Karamchand, Rory F Leisegang
    World Journal of Diabetes.2023; 14(7): 939.     CrossRef
  • Comparative efficacy and safety profile of once-weekly Semaglutide versus once-daily Sitagliptin as an add-on to metformin in patients with type 2 diabetes: a systematic review and meta-analysis
    Tirath Patel, Fnu Nageeta, Rohab Sohail, Tooba Shaukat Butt, Shyamala Ganesan, Fnu Madhurita, Muhammad Ahmed, Mahrukh Zafar, Wirda Zafar, Mohammad Uzair Zaman, Giustino Varrassi, Mahima Khatri, Satesh Kumar
    Annals of Medicine.2023;[Epub]     CrossRef
  • Bexagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, for improvement of glycemia in type 2 diabetes mellitus: a systematic review and meta-analysis
    Sagar Dholariya, Siddhartha Dutta, Ragini Singh, Deepak Parchwani, Amit Sonagra, Mehul Kaliya
    Expert Opinion on Pharmacotherapy.2023; 24(18): 2187.     CrossRef
  • Analysis of the management and therapeutic performance of diabetes mellitus employing special target
    Hong-Yan Sun, Xiao-Yan Lin
    World Journal of Diabetes.2023; 14(12): 1721.     CrossRef
  • Zinc Chloride Enhances the Antioxidant Status, Improving the Functional and Structural Organic Disturbances in Streptozotocin-Induced Diabetes in Rats
    Irina Claudia Anton, Liliana Mititelu-Tartau, Eliza Gratiela Popa, Mihaela Poroch, Vladimir Poroch, Ana-Maria Pelin, Liliana Lacramioara Pavel, Ilie Cristian Drochioi, Gina Eosefina Botnariu
    Medicina.2022; 58(11): 1620.     CrossRef
Close layer
Original Article
Diabetes, Obesity and Metabolism
Big Data Articles (National Health Insurance Service Database)
Frequency of Exposure to Impaired Fasting Glucose and Risk of Mortality and Cardiovascular Outcomes
Seung-Hwan Lee, Kyungdo Han, Hyuk-Sang Kwon, Mee Kyoung Kim
Endocrinol Metab. 2021;36(5):1007-1015.   Published online October 21, 2021
DOI: https://doi.org/10.3803/EnM.2021.1218
  • 3,707 View
  • 126 Download
  • 12 Web of Science
  • 11 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Metabolic abnormalities, such as impaired fasting glucose (IFG), are dynamic phenomena; however, it is unclear whether the timing of IFG exposure and cumulative exposure to IFG are related to cardiovascular disease (CVD) and mortality risk.
Methods
Data were extracted from a nationwide population-based cohort in South Korea for adults (n=2,206,679) who were free of diabetes and had 4 years of consecutive health examination data. Fasting blood glucose levels of 100 to 125 mg/dL were defined as IFG, and the number of IFG diagnoses for each adult in the 4-year period was tabulated as the IFG exposure score (range, 0 to 4). Adults with persistent IFG for the 4-year period received a score of 4.
Results
The median follow-up was 8.2 years. There were 24,820 deaths, 13,502 cases of stroke, and 13,057 cases of myocardial infarction (MI). IFG exposure scores of 1, 2, 3, and 4 were associated with all-cause mortality (multivariable-adjusted hazard ratio [aHR], 1.11; 95% confidence interval [CI], 1.08 to 1.15; aHR, 1.16; 95% CI, 1.12 to 1.20; aHR, 1.20; 95% CI, 1.15 to 1.25; aHR, 1.18; 95% CI, 1.11 to 1.25, respectively) compared with an IFG exposure score of 0. Adjusting for hypertension and dyslipidemia attenuated the slightly increased risk of MI or stroke associated with high IFG exposure scores, but significant associations for allcause mortality remained.
Conclusion
The intensity of IFG exposure was associated with an elevated risk of all-cause mortality, independent of cardiovascular risk factors. The association between IFG exposure and CVD risk was largely mediated by the coexistence of dyslipidemia and hypertension.

Citations

Citations to this article as recorded by  
  • A nationwide cohort study on diabetes severity and risk of Parkinson disease
    Kyungdo Han, Bongsung Kim, Seung Hwan Lee, Mee Kyoung Kim
    npj Parkinson's Disease.2023;[Epub]     CrossRef
  • Diabetes severity is strongly associated with the risk of active tuberculosis in people with type 2 diabetes: a nationwide cohort study with a 6-year follow-up
    Ji Young Kang, Kyungdo Han, Seung-Hwan Lee, Mee Kyoung Kim
    Respiratory Research.2023;[Epub]     CrossRef
  • Construction and Validation of a Model for Predicting Impaired Fasting Glucose Based on More Than 4000 General Population
    Cuicui Wang, Xu Zhang, Chenwei Li, Na Li, Xueni Jia, Hui Zhao
    International Journal of General Medicine.2023; Volume 16: 1415.     CrossRef
  • Factors Affecting High Body Weight Variability
    Kyungdo Han, Mee Kyoung Kim
    Journal of Obesity & Metabolic Syndrome.2023; 32(2): 163.     CrossRef
  • Exposure to perfluoroalkyl and polyfluoroalkyl substances and risk of stroke in adults: a meta-analysis
    Min Cheol Chang, Seung Min Chung, Sang Gyu Kwak
    Reviews on Environmental Health.2023;[Epub]     CrossRef
  • Cumulative effect of impaired fasting glucose on the risk of dementia in middle-aged and elderly people: a nationwide cohort study
    Jin Yu, Kyu-Na Lee, Hun-Sung Kim, Kyungdo Han, Seung-Hwan Lee
    Scientific Reports.2023;[Epub]     CrossRef
  • A Longitudinal Retrospective Observational Study on Obesity Indicators and the Risk of Impaired Fasting Glucose in Pre- and Postmenopausal Women
    Myung Ji Nam, Hyunjin Kim, Yeon Joo Choi, Kyung-Hwan Cho, Seon Mee Kim, Yong-Kyun Roh, Kyungdo Han, Jin-Hyung Jung, Yong-Gyu Park, Joo-Hyun Park, Do-Hoon Kim
    Journal of Clinical Medicine.2022; 11(10): 2795.     CrossRef
  • Current Trends of Big Data Research Using the Korean National Health Information Database
    Mee Kyoung Kim, Kyungdo Han, Seung-Hwan Lee
    Diabetes & Metabolism Journal.2022; 46(4): 552.     CrossRef
  • Lipid cutoffs for increased cardiovascular disease risk in non-diabetic young people
    Mee Kyoung Kim, Kyungdo Han, Hun-Sung Kim, Kun-Ho Yoon, Seung-Hwan Lee
    European Journal of Preventive Cardiology.2022; 29(14): 1866.     CrossRef
  • Low-Density Lipoprotein Cholesterol Level, Statin Use and Myocardial Infarction Risk in Young Adults
    Heekyoung Jeong, Kyungdo Han, Soon Jib Yoo, Mee Kyoung Kim
    Journal of Lipid and Atherosclerosis.2022; 11(3): 288.     CrossRef
  • Additive interaction of diabetes mellitus and chronic kidney disease in cancer patient mortality risk
    Seohyun Kim, Gyuri Kim, Jae Hyeon Kim
    Scientific Reports.2022;[Epub]     CrossRef
Close layer
Review Articles
Diabetes
Continuous Glucose Monitoring in the Hospital
M. Citlalli Perez-Guzman, Trisha Shang, Jennifer Y. Zhang, Donna Jornsay, David C. Klonoff
Endocrinol Metab. 2021;36(2):240-255.   Published online March 31, 2021
DOI: https://doi.org/10.3803/EnM.2021.201
  • 16,180 View
  • 645 Download
  • 25 Web of Science
  • 22 Crossref
AbstractAbstract PDFPubReader   ePub   
Continuous glucose monitors (CGMs) have suddenly become part of routine care in many hospitals. The coronavirus disease 2019 (COVID-19) pandemic has necessitated the use of new technologies and new processes to care for hospitalized patients, including diabetes patients. The use of CGMs to automatically and remotely supplement or replace assisted monitoring of blood glucose by bedside nurses can decrease: the amount of necessary nursing exposure to COVID-19 patients with diabetes; the amount of time required for obtaining blood glucose measurements, and the amount of personal protective equipment necessary for interacting with patients during the blood glucose testing. The United States Food and Drug Administration (FDA) is now exercising enforcement discretion and not objecting to certain factory-calibrated CGMs being used in a hospital setting, both to facilitate patient care and to obtain performance data that can be used for future regulatory submissions. CGMs can be used in the hospital to decrease the frequency of fingerstick point of care capillary blood glucose testing, decrease hyperglycemic episodes, and decrease hypoglycemic episodes. Most of the research on CGMs in the hospital has focused on their accuracy and only recently outcomes data has been reported. A hospital CGM program requires cooperation of physicians, bedside nurses, diabetes educators, and hospital administrators to appropriately select and manage patients. Processes for collecting, reviewing, storing, and responding to CGM data must be established for such a program to be successful. CGM technology is advancing and we expect that CGMs will be increasingly used in the hospital for patients with diabetes.

Citations

Citations to this article as recorded by  
  • Accuracy and Safety of the 15-Day CareSens Air Continuous Glucose Monitoring System
    Kyung-Soo Kim, Seung-Hwan Lee, Won Sang Yoo, Cheol-Young Park
    Diabetes Technology & Therapeutics.2024;[Epub]     CrossRef
  • Glucose management in critically ill adults: A qualitative study from the experiences of health care providers
    Miao Huang, Li Yang, Chuanlai Zhang, Xiuni Gan
    Heliyon.2024; 10(3): e24545.     CrossRef
  • The Need for Data Standards and Implementation Policies to Integrate CGM Data into the Electronic Health Record
    Juan Espinoza, Nicole Y. Xu, Kevin T. Nguyen, David C. Klonoff
    Journal of Diabetes Science and Technology.2023; 17(2): 495.     CrossRef
  • Staff knowledge, attitudes and practices regarding glycaemic management in adult intensive care units: A national survey
    Miao Huang, Ruiqi Yang, Chuanlai Zhang, Xiuni Gan
    Nursing in Critical Care.2023; 28(6): 931.     CrossRef
  • Continuous Glucose Monitoring for Patients with COVID-19 Pneumonia: Initial Experience at a Tertiary Care Center
    Adrian G. Dumitrascu, Michelle F. Perry, Rebecca J. Boone, Maria P. Guzman, Razvan M. Chirila, Allyson W. McNally, Dorin T. Colibaseanu, Shon E. Meek, Colleen T. Ball, Launia J. White, Ana-Maria Chindris
    Endocrine Practice.2023; 29(3): 155.     CrossRef
  • Use of Continuous Glucose Monitors to Manage Type 1 Diabetes Mellitus: Progress, Challenges, and Recommendations
    Jared G Friedman, Zulma Cardona Matos, Emily D Szmuilowicz, Grazia Aleppo
    Pharmacogenomics and Personalized Medicine.2023; Volume 16: 263.     CrossRef
  • Type 1 Diabetes Overview and Perioperative Management
    Grace B. Nelson, Kathryn M. Sumpter
    Orthopedic Clinics of North America.2023; 54(3): 287.     CrossRef
  • Real-Time Continuous Glucose Monitoring in the Hospital: A Real-World Experience
    Samantha R. Spierling Bagsic, Addie L. Fortmann, Rebekah Belasco, Alessandra Bastian, Suzanne Lohnes, Anna Ritko, Haley Sandoval, Mariya Chichmarenko, Emily C. Soriano, Laura Talavera, Athena Philis-Tsimikas
    Journal of Diabetes Science and Technology.2023; 17(3): 656.     CrossRef
  • Implementation of Continuous Glucose Monitoring in Critical Care: A Scoping Review
    Eileen R. Faulds, Kathleen M. Dungan, Molly McNett
    Current Diabetes Reports.2023; 23(6): 69.     CrossRef
  • Clinical Use of Continuous Glucose Monitoring in Critically Ill Pediatric Patients with Diabetic Ketoacidosis
    Esther Park, Minsun Kim
    Diabetes Technology & Therapeutics.2023; 25(8): 529.     CrossRef
  • Comparison of Glycemia Risk Index with Time in Range for Assessing Glycemic Quality
    Ji Yoon Kim, Jee Hee Yoo, Jae Hyeon Kim
    Diabetes Technology & Therapeutics.2023; 25(12): 883.     CrossRef
  • A randomized trial of continuous glucose monitoring to improve post‐transplant glycemic control
    Nicholas Jandovitz, Sam J. George, Mersema Abate, Adam M. Kressel, Alexandra C. Bolognese, Lawrence Lau, Vinay Nair, Elliot Grodstein
    Clinical Transplantation.2023;[Epub]     CrossRef
  • More Green, Less Red: How Color Standardization May Facilitate Effective Use of CGM Data
    Richard M. Bergenstal, Gregg D. Simonson, Lutz Heinemann
    Journal of Diabetes Science and Technology.2022; 16(1): 3.     CrossRef
  • Continuous glucose monitoring in the hospital: an update in the era of COVID-19
    Chikara Gothong, Lakshmi G. Singh, Medha Satyarengga, Elias K. Spanakis
    Current Opinion in Endocrinology, Diabetes & Obesity.2022; 29(1): 1.     CrossRef
  • Breakthrough technology for in-hospital glucose monitoring
    David Kerr, David Klonoff
    The Lancet Diabetes & Endocrinology.2022; 10(5): 304.     CrossRef
  • The Role of the Diabetes Care and Education Specialist in the Hospital Setting

    The Science of Diabetes Self-Management and Care.2022; 48(3): 184.     CrossRef
  • Real-Time Monitoring of Blood Parameters in the Intensive Care Unit: State-of-the-Art and Perspectives
    Rebecca Bockholt, Shaleen Paschke, Lars Heubner, Bergoi Ibarlucea, Alexander Laupp, Željko Janićijević, Stephanie Klinghammer, Sascha Balakin, Manfred F. Maitz, Carsten Werner, Gianaurelio Cuniberti, Larysa Baraban, Peter Markus Spieth
    Journal of Clinical Medicine.2022; 11(9): 2408.     CrossRef
  • Novel Glycemic Index Based on Continuous Glucose Monitoring to Predict Poor Clinical Outcomes in Critically Ill Patients: A Pilot Study
    Eun Yeong Ha, Seung Min Chung, Il Rae Park, Yin Young Lee, Eun Young Choi, Jun Sung Moon
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Stress-Induced Hyperglycemia: Consequences and Management
    Deepanjali Vedantam, Devyani S Poman, Lakshya Motwani, Nailah Asif, Apurva Patel, Krishna Kishore Anne
    Cureus.2022;[Epub]     CrossRef
  • Hospital Diabetes Meeting 2022
    Jingtong Huang, Andrea M. Yeung, Kevin T. Nguyen, Nicole Y. Xu, Jean-Charles Preiser, Robert J. Rushakoff, Jane Jeffrie Seley, Guillermo E. Umpierrez, Amisha Wallia, Andjela T. Drincic, Roma Gianchandani, M. Cecilia Lansang, Umesh Masharani, Nestoras Math
    Journal of Diabetes Science and Technology.2022; 16(5): 1309.     CrossRef
  • Effects of Patient-Driven Lifestyle Modification Using Intermittently Scanned Continuous Glucose Monitoring in Patients With Type 2 Diabetes: Results From the Randomized Open-label PDF Study
    Hun Jee Choe, Eun-Jung Rhee, Jong Chul Won, Kyong Soo Park, Won-Young Lee, Young Min Cho
    Diabetes Care.2022; 45(10): 2224.     CrossRef
  • The Devil Is in the Details: Use, Limitations, and Implementation of Continuous Glucose Monitoring in the Inpatient Setting
    Rebecca Rick Longo, Renu Joshi
    Diabetes Spectrum.2022; 35(4): 405.     CrossRef
Close layer
Diabetes
Best Achievements in Clinical Medicine in Diabetes and Dyslipidemia in 2020
Eun-Jung Rhee, Mee-Kyung Kim, Won-Young Lee
Endocrinol Metab. 2021;36(1):41-50.   Published online February 24, 2021
DOI: https://doi.org/10.3803/EnM.2021.106
  • 4,184 View
  • 175 Download
  • 3 Web of Science
  • 4 Crossref
AbstractAbstract PDFPubReader   ePub   
Over the last two decades, our understanding of diabetes and treatment strategies have evolved tremendously, from scientific, mechanistic, and human perspectives. The categories of anti-diabetic medications expanded from a few to numerous, enabling clinicians to personalize diabetes care and treatment. Thanks to rapid growth in the field of science and medical engineering, newer treatment options are coming to the market with various advantages and disadvantages to be aware of. Therefore, clinicians should rapidly adopt new trends based on guidelines and data from many clinical trials in the field of diabetes. In the treatment of dyslipidemia, trends and guidelines are changing every year, and novel therapies are being developed. In this review, we would like to summarize the major achievements in clinical medicine in 2020 in the field of diabetes mellitus and dyslipidemia.

Citations

Citations to this article as recorded by  
  • Efficacy and safety of enavogliflozin versus dapagliflozin added to metformin plus gemigliptin treatment in patients with type 2 diabetes: A double-blind, randomized, comparator-active study: ENHANCE-D study
    Kyung-Soo Kim, Kyung Ah Han, Tae Nyun Kim, Cheol-Young Park, Jung Hwan Park, Sang Yong Kim, Yong Hyun Kim, Kee Ho Song, Eun Seok Kang, Chul Sik Kim, Gwanpyo Koh, Jun Goo Kang, Mi Kyung Kim, Ji Min Han, Nan Hee Kim, Ji Oh Mok, Jae Hyuk Lee, Soo Lim, Sang S
    Diabetes & Metabolism.2023; 49(4): 101440.     CrossRef
  • Effects of exercise initiation and smoking cessation after new-onset type 2 diabetes mellitus on risk of mortality and cardiovascular outcomes
    Mee Kyoung Kim, Kyungdo Han, Bongsung Kim, Jinyoung Kim, Hyuk-Sang Kwon
    Scientific Reports.2022;[Epub]     CrossRef
  • Combined Effects of Obesity and Dyslipidaemia on the Prevalence of Diabetes Amongst Adults Aged ≥45 Years: Evidence from a Nationally Representative Cross-Sectional Study
    Simin Zhang, Donghan Sun, Xiaoyi Qian, Li Li, Wenwen Wu
    International Journal of Environmental Research and Public Health.2022; 19(13): 8036.     CrossRef
  • Low-Density Lipoprotein Cholesterol Level, Statin Use and Myocardial Infarction Risk in Young Adults
    Heekyoung Jeong, Kyungdo Han, Soon Jib Yoo, Mee Kyoung Kim
    Journal of Lipid and Atherosclerosis.2022; 11(3): 288.     CrossRef
Close layer
Diabetes
Lessons from Use of Continuous Glucose Monitoring Systems in Digital Healthcare
Hun-Sung Kim, Kun-Ho Yoon
Endocrinol Metab. 2020;35(3):541-548.   Published online September 22, 2020
DOI: https://doi.org/10.3803/EnM.2020.675
  • 6,658 View
  • 181 Download
  • 7 Web of Science
  • 10 Crossref
AbstractAbstract PDFPubReader   ePub   
We live in a digital world where a variety of wearable medical devices are available. These technologies enable us to measure our health in our daily lives. It is increasingly possible to manage our own health directly through data gathered from these wearable devices. Likewise, healthcare professionals have also been able to indirectly monitor patients’ health. Healthcare professionals have accepted that digital technologies will play an increasingly important role in healthcare. Wearable technologies allow better collection of personal medical data, which healthcare professionals can use to improve the quality of healthcare provided to the public. The use of continuous glucose monitoring systems (CGMS) is the most representative and desirable case in the adoption of digital technology in healthcare. Using the case of CGMS and examining its use from the perspective of healthcare professionals, this paper discusses the necessary adjustments required in clinical practices. There is a need for various stakeholders, such as medical staff, patients, industry partners, and policy-makers, to utilize and harness the potential of digital technology.

Citations

Citations to this article as recorded by  
  • Managing Talent Among Healthcare Human Resource: Strategies for a New Normal
    Divya Aggarwal, Vijit Chaturvedi, Anandhi Ramachandran, Taniya Singh
    Journal of Health Management.2024;[Epub]     CrossRef
  • Current status of remote collaborative care for hypertension in medically underserved areas
    Seo Yeon Baik, Kyoung Min Kim, Hakyoung Park, Jiwon Shinn, Hun-Sung Kim
    Cardiovascular Prevention and Pharmacotherapy.2024; 6(1): 33.     CrossRef
  • Using medical big data for clinical research and legal considerations for the protection of personal information: the double-edged sword
    Raeun Kim, Jiwon Shinn, Hun-Sung Kim
    Cardiovascular Prevention and Pharmacotherapy.2024; 6(1): 8.     CrossRef
  • Diverse perspectives on remote collaborative care for chronic disease management
    Seo Yeon Baik, Hakyoung Park, Jiwon Shinn, Hun-Sung Kim
    Cardiovascular Prevention and Pharmacotherapy.2024; 6(1): 26.     CrossRef
  • Patent analysis of digital sensors for continuous glucose monitoring
    Olena Litvinova, Magdalena Eitenberger, Aylin Bilir, Andy Wai Kan Yeung, Emil D. Parvanov, ArunSundar MohanaSundaram, Jarosław Olav Horbańczuk, Atanas G. Atanasov, Harald Willschke
    Frontiers in Public Health.2023;[Epub]     CrossRef
  • Personalized Nutrition 2020: Proceedings from the American Nutrition Association’s 61st Annual Summit
    Victoria A. Y. Behm, Corinne L. Bush
    Journal of the American College of Nutrition.2021; 40(4): 397.     CrossRef
  • Towards Telemedicine Adoption in Korea: 10 Practical Recommendations for Physicians
    Hun-Sung Kim
    Journal of Korean Medical Science.2021;[Epub]     CrossRef
  • Perceptron: Basic Principles of Deep Neural Networks
    Eung-Hee Kim, Hun-Sung Kim
    Cardiovascular Prevention and Pharmacotherapy.2021; 3(3): 64.     CrossRef
  • Lack of Acceptance of Digital Healthcare in the Medical Market: Addressing Old Problems Raised by Various Clinical Professionals and Developing Possible Solutions
    Jong Il Park, Hwa Young Lee, Hyunah Kim, Jisan Lee, Jiwon Shinn, Hun-Sung Kim
    Journal of Korean Medical Science.2021;[Epub]     CrossRef
  • Digital health and diabetes: experience from India
    Jothydev Kesavadev, Gopika Krishnan, Viswanathan Mohan
    Therapeutic Advances in Endocrinology and Metabolism.2021; 12: 204201882110546.     CrossRef
Close layer
Original Articles
Clinical Study
Fasting Plasma Glucose Level Independently Predicts the Mortality of Patients with Coronavirus Disease 2019 Infection: A Multicenter, Retrospective Cohort Study
Min Cheol Chang, Jong-Moon Hwang, Jae-Han Jeon, Sang Gyu Kwak, Donghwi Park, Jun Sung Moon
Endocrinol Metab. 2020;35(3):595-601.   Published online August 26, 2020
DOI: https://doi.org/10.3803/EnM.2020.719
  • 6,823 View
  • 181 Download
  • 15 Web of Science
  • 16 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Coronavirus disease 2019 (COVID-19) has become a global pandemic, which prompts a consensus for the necessity to seek risk factors for this critical disease. Risk factors affecting mortality of the disease remain elusive. Diabetes and hyperglycemia are known to negatively affect a host’s antiviral immunity. We evaluated the relationship between a history of diabetes, fasting plasma glucose (FPG) levels and mortality among severely ill patients with COVID-19.
Methods
This was a retrospective cohort study that assessed 106 adult inpatients (aged ≥18 years) from two tertiary hospitals in Daegu, South Korea. The participants were transferred to tertiary hospitals because their medical condition required immediate intensive care. The demographic and laboratory data were compared between COVID-19 patients who survived and those who did not.
Results
Compared with the survivor group, age, and the proportions of diabetes, chronic lung disease and FPG were significantly higher in the deceased group. In the Cox proportional hazards regression model for survival analysis, FPG level and age were identified as significant predictors of mortality (P<0.05). The threshold values for predicting high mortality were age >68 years and FPG of 168 mg/dL, respectively. Among those without diabetes, high FPG remained a significant predictor of mortality (P<0.04).
Conclusion
High FPG levels significantly predicted mortality in COVID-19, regardless of a known history of diabetes. These results suggest intensive monitoring should be provided to COVID-19 patients who have a high FPG level.

Citations

Citations to this article as recorded by  
  • Fasting Plasma Glucose Levels at the Time of Admission Predict 90-Day Mortality in Patients with Viral Pneumonia. A Prospective Study
    Jie Xu, Jianyu Zhao, Liyuan Wu, Xinxin Lu
    Experimental and Clinical Endocrinology & Diabetes.2023; 131(05): 290.     CrossRef
  • Influence of Fasting Plasma Glucose Level on Admission of COVID-19 Patients: A Retrospective Study
    Yingying Zhao, Huichun Xing, Yong Xu
    Journal of Diabetes Research.2022; 2022: 1.     CrossRef
  • The Role of Diabetes and Hyperglycemia on COVID-19 Infection Course—A Narrative Review
    Evangelia Tzeravini, Eleftherios Stratigakos, Chris Siafarikas, Anastasios Tentolouris, Nikolaos Tentolouris
    Frontiers in Clinical Diabetes and Healthcare.2022;[Epub]     CrossRef
  • Novel Glycemic Index Based on Continuous Glucose Monitoring to Predict Poor Clinical Outcomes in Critically Ill Patients: A Pilot Study
    Eun Yeong Ha, Seung Min Chung, Il Rae Park, Yin Young Lee, Eun Young Choi, Jun Sung Moon
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Heterogeneity and Risk of Bias in Studies Examining Risk Factors for Severe Illness and Death in COVID-19: A Systematic Review and Meta-Analysis
    Abraham Degarege, Zaeema Naveed, Josiane Kabayundo, David Brett-Major
    Pathogens.2022; 11(5): 563.     CrossRef
  • Global, Regional and National Burden of Cancers Attributable to High Fasting Plasma Glucose in 204 Countries and Territories, 1990-2019
    Saeid Safiri, Seyed Aria Nejadghaderi, Nahid Karamzad, Jay S. Kaufman, Kristin Carson-Chahhoud, Nicola Luigi Bragazzi, Mark J. M. Sullman, Mohammad Reza Beyranvand, Mohammad Ali Mansournia, Amir Almasi-Hashiani, Gary S. Collins, Ali-Asghar Kolahi
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • COVID-19 and diabetes—Two giants colliding: From pathophysiology to management
    Maria Chiara Pelle, Isabella Zaffina, Michele Provenzano, Giovenale Moirano, Franco Arturi
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • SARS-CoV-2 omicron variant clearance delayed in breakthrough cases with elevated fasting blood glucose
    Xiujun Zhang, Guocan Si, Huifen Lu, Wei Zhang, Shuqin Zheng, Zeyu Huang, Longgen Liu, Yuan Xue, Guojun Zheng
    Virology Journal.2022;[Epub]     CrossRef
  • Hyperglycemia is Associated With Increased Mortality in Critically Ill Patients With COVID-19
    Alon Y. Mazori, Ilana Ramer Bass, Lili Chan, Kusum S. Mathews, Deena R. Altman, Aparna Saha, Howard Soh, Huei Hsun Wen, Sonali Bose, Emily Leven, Jing Gennie Wang, Gohar Mosoyan, Pattharawin Pattharanitima, Giampaolo Greco, Emily J. Gallagher
    Endocrine Practice.2021; 27(2): 95.     CrossRef
  • The common risk factors for progression and mortality in COVID-19 patients: a meta-analysis
    Li Zhang, Jie Hou, Fu-Zhe Ma, Jia Li, Shuai Xue, Zhong-Gao Xu
    Archives of Virology.2021; 166(8): 2071.     CrossRef
  • Dyslipidaemia and mortality in COVID-19 patients: a meta-analysis
    M Zuin, G Rigatelli, C Bilato, C Cervellati, G Zuliani, L Roncon
    QJM: An International Journal of Medicine.2021; 114(6): 390.     CrossRef
  • National early warning score on admission as risk factor for invasive mechanical ventilation in COVID-19 patients
    Min Cheol Chang, Tae Uk Kim, Donghwi Park
    Medicine.2021; 100(19): e25917.     CrossRef
  • Thyroid Hormone Profile and Its Prognostic Impact on the Coronavirus Disease 2019 in Korean Patients
    Jiyeon Ahn, Min Kyung Lee, Jae Hyuk Lee, Seo Young Sohn
    Endocrinology and Metabolism.2021; 36(4): 769.     CrossRef
  • Diabetes, hypertension, body mass index, smoking and COVID-19-related mortality: a systematic review and meta-analysis of observational studies
    Yahya Mahamat-Saleh, Thibault Fiolet, Mathieu Edouard Rebeaud, Matthieu Mulot, Anthony Guihur, Douae El Fatouhi, Nasser Laouali, Nathan Peiffer-Smadja, Dagfinn Aune, Gianluca Severi
    BMJ Open.2021; 11(10): e052777.     CrossRef
  • COVID-19 und Diabetes: Folgen der Pandemie
    Baptist Gallwitz, Wolfgang Rathmann
    Deutsches Ärzteblatt Online.2021;[Epub]     CrossRef
  • Incidence of Post-Traumatic Stress Disorder after Coronavirus Disease
    Min Cheol Chang, Donghwi Park
    Healthcare.2020; 8(4): 373.     CrossRef
Close layer
Clinical Usefulness of Glucose Testing from the Forearm in Diabetic Patients.
Sang Wook Lee, Suk Chon, Seungjoon Oh, Jeong taek Woo, Sung Woon Kim, Jin Woo Kim, Young Seol Kim, Jeong Ryung Paeng, Gwanpyo Koh, Hak Hyun Nam
J Korean Endocr Soc. 2006;21(4):281-289.   Published online August 1, 2006
DOI: https://doi.org/10.3803/jkes.2006.21.4.281
  • 1,732 View
  • 21 Download
  • 1 Crossref
AbstractAbstract PDF
BACKGROUND
Self monitoring of blood glucose plays an important role in the management of diabetes. However, traditional finger prick testing causes pain and so compliance with self monitoring of blood glucose is usually poor. Using an alternative site for sampling may reduce the level of pain and be beneficial for improving the compliance of diabetic patients. We evaluated the accuracy and acceptability of blood glucose testing from the forearm by analyzing the performance of the CareSens(R) (i-Sens, Inc. Korea) device for diabetic patients. METHODS: We measured the glucose level at the forearm by use of CareLance(R) (vaccum assisted lancing device) and also at the finger tip simultaneously by use of the CareSens(R) device at fasting and postprandial 2 hours, respectively. At the same time, the glucose levels of venous samples were checked by the laboratory method (BIOSEN 5030, EKF, Germany) and compared with those glucose level measured by the CareSens(R) device. We also checked the ease of use of the CareLance(R) and the associated pain of the patients by means of a visual analogue scale (VAS) at the time of blood sampling. RESULTS: The glucose level obtained from the forearm and finger tip correlated well with that from the laboratory method, respectively. Error grid analysis showed that 100% of the measurements were clinically acceptable; forearm blood glucose testing by use of CareLance(R) was less painful and it was as easy to use as the finger prick (P < 0.05 and P = 0.04, respectively). CONCLUSION: Forearm testing is an acceptable alternative to finger prick testing for measuring blood glucose in diabetic patients.

Citations

Citations to this article as recorded by  
  • Accuracy Evaluation of the Alternative Site Blood Glucose Test Using Error Grid
    Kyung-Soon Park, Eun-Jong Cha
    Journal of Biomedical Engineering Research.2011; 32(1): 25.     CrossRef
Close layer

Endocrinol Metab : Endocrinology and Metabolism